First patient dosed in Australia where 3 clinical trial sites have been activated.The trial will enrol advanced colorectal cancer patients whose cancer.
Lirafugratinib demonstrated clinical activity in multiple subsets of patients with FGFR2-altered solid tumors, including those with FGFR2-altered hormone receptor–positive, HER2-negative breast cancer.
The addition of bexmarilimab to standard-of-care azacitidine or azacitidine plus venetoclax continued to elicit responses in patients with relapsed or refractory acute myeloid leukemia and those with myelodysplastic syndrome who were refractory to hypomethylating agents.
Phase 1b/2 pepinemab/PDAC study update to be presented on September 29 at special AACR meeting New ActivMAb® application to be reviewed on September 28 at CHI s 20th Annual Discovery on.
27.09.2023 - Phase 1b/2 pepinemab/PDAC study update to be presented on September 29 at special AACR meeting New ActivMAb application to be reviewed on September 28 at CHI s 20th Annual Discovery on Target (DOT) conference ROCHESTER, N.Y., Sept. . Seite 1